– USA, CA – Biomerica Inc. (NASDAQ: BMRA) today announced the appointment of Cathy Coste to its Bard as a new Independent Director, effective September 3, 2020.
Ms. Coste has also been elected to chair the Audit Committee and to be a member of the Nominating and Corporate Governance Committee.
Cathy Coste is a Senior Partner at Deloitte and Touche, LLP, and is retiring in September 2020. She has spent thirty-two years in both corporate and professional services positions leading global finance, internal audit and operations teams. For the past six years, Cathy has served as Deloitte’s Life Sciences Industry Executive Leader. Ms. Coste is known for her expertise in governance, audit, risk and controls, and compliance and has served over 50 companies in the life science, technology, and consumer industries.
The company also announced the appointment of Steve Sloan as the new CFO, effective September 3, 2020, succeeding Janet Moore who has decided to retire and pursue personal interests.
Mr. Sloan’s background and experience include thirteen years at General Electric with roles in internal audit, corporate finance and manufacturing finance. Most recently, Mr. Sloan spent ten years with medical device maker, Medtronic. At Medtronic, Mr. Sloan worked in four divisions, most recently serving as a divisional finance director.
Ms. Moore, who also serves as a member of the Board of Directors and Corporate Secretary, will continue to serve as a member of the Board and as Corporate Secretary until the Company’s Annual Meeting on December 10, 2020. At that time, Ms. Moore will also be leaving the Board.
“I personally want to thank Janet for being a trusted advisor and leader throughout her career at the Company in serving as CFO, Board Member and Secretary. At the same time, I’m excited to have Steve Sloan join our executive management team as CFO. Steve brings great knowledge, experience and energy to the position and I am confident he will play a key role in helping us achieve our goals of building Biomerica. Finally, on behalf of the Board, I welcome Cathy Coste and I am looking forward to working with her, especially given her experience in the life sciences industry.” said Cathy Coste.
She added: “Biomerica has a bold vision of developing a diagnostic guided therapy with its InFoods product. I’m honored to assume the role of Audit Committee Chairman and look forward to an exciting new fiscal year and beyond for Biomerica.”
About Biomerica
Biomerica, Inc. is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company’s products are designed to enhance the health and well-being of people while reducing total healthcare costs. Biomerica primarily focus is on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
For more information: http://www.biomerica.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.